激酶的动力学. 使用古老的蛋白激酶来解开现代癌症药物的机制
C Wilson1, R V Agafonov1, M Hoemberger1
1Howard Hughes Medical Institute and Department of Biochemistry, Brandeis University, Waltham, MA 02452, USA.
概括
对Src和Abl瘤基因的进化重建揭示了癌症药物Gleevec如何获得特异性. 这项研究详细介绍了Gleevec背后的原子化机制.
科学领域:
- 生物化学 生物化学
- 进化生物学 进化生物学
- 结构生物学 结构生物学
背景情况:
- 蛋白质的功能是由能量格局控制的,进化通过改变这些格局来改变这些格局.
- 人类瘤基因Src和Abl共享一个共同的祖先,为研究提供了一个进化途径.
- 了解瘤基因进化对于开发向癌症疗法至关重要.
研究的目的:
- 重建 Src 和 Abl 瘤基因之间的进化途径.
- 通过进化重建来阐明Gleevec选择性的原子化机制.
- 了解能源景观如何演变并影响药物特异性的理解.
主要方法:
- 重建 Src 和 Abl 瘤基因的共同祖先.
- 确定重建的共同祖先的X射线结构.
- 进行稳定状态前的运动分析.
主要成果:
- 向ABL的进化轨迹获得了Gleevec的亲和力,而向Src的轨迹失去了它.
- 格利维克特异性的关键机制涉及诱导适合平衡的转变.
- 这种诱导适应平衡也与T315I抗性突变有关.
结论:
- 该研究通过追踪其进化收益,揭示了Gleevec特异性的精确机制.
- 蛋白质能量格局的进化变化决定了药物向相互作用.
- 对能源景观演变的洞察力为了解耐药性和设计新疗法提供了一个框架.
相关概念视频
M-Cdk Drives Transition Into Mitosis
6.8K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression
1.8K
1.8K
Inhibition of Cdk Activity
6.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Protein Kinases and Phosphatases
15.7K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.7K
Protein Kinases and Phosphatases
4.7K
4.7K


